Novo Nordisk has launched the first GLP-1 weight-loss pill in the US at a lower price than injections. The once-daily Wegovy pill recently received US regulatory approval and is now available nationwide. It is the only pill version that mimics the GLP-1 hormone to suppress appetite. Self-pay patients can access the starting dose for $149 per month, far below injectable list prices. The launch accelerates price competition with rival Eli Lilly, maker of Mounjaro and Zepbound. Novo hopes the pill’s lower cost and needle-free format will expand access for obesity treatment. The drug is currently approved only in the US, with UK approval under review.
Novo Nordisk Launches Wegovy Pill in US, Intensifying Weight-Loss Drug Price War
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.
Add A Comment
